UK-based startup Zya has raised a £11.5m ($15m) Series A round led by Astanor to advance an enzyme that converts up to a third of the sugar in foods into fiber after consumption, enabling firms to improve the nutritional profile of foods without reformulating them.
The round, which also attracted backing from Ahren Innovation Capital, Red Bull Ventures, Zubi Capital, Phase Change and Meach Cove Capital, will support human studies, regulatory work and commercial partnerships as Zya prepares to launch its first products with US food manufacturers by the end of 2027.
Its first ingredient, Convero, is an enzyme produced via precision fermentation which Zya claims converts around 30% of sucrose in foods into fructooligosaccharides (FOS), a class of prebiotic fibers that resist digestion in the small intestine and are fermented by bacteria in the colon.
Unlike conventional sugar-reduction approaches, which typically involve replacing sugar with alternative sweeteners and bulking agents, Zya leaves the sugar in foods untouched until it is consumed.
This could be particularly attractive in categories such as chocolate, baked goods and confectionery, where sugar performs multiple functional roles and is notoriously difficult to replace without compromising the eating experience, cofounder Dr Joshua Sauer told AgFunderNews.
“Convero is aimed at the mass market, not a niche functional-ingredient trend and takes a sugar surplus into the fiber Americans are short of.”
Zya has completed feasibility projects with multinational food manufacturers, several of which are progressing towards co-development agreements, and has more than 100 companies in its commercial pipeline, claimed Sauer.
How does it work?
Founded by Oxford University biochemists Joshua Sauer PhD (CEO), and Niels Leckie, PhD (CSO) in 2018 with seed funding from Astanor in 2022, Zya is initially targeting low-moisture products such as chocolate, cereal bars, biscuits and confectionery, where the enzyme can remain inactive until it reaches the digestive tract.
Once the food enters the stomach and the enzyme dissolves in the aqueous environment, it begins converting sucrose into FOS.
The enzyme, an inulosucrase, acts on sucrose, which ordinarily breaks down into glucose and fructose in the small intestine before being absorbed into the bloodstream.
“Our enzyme does the same thing effectively, but after breaking the sugar in half, it attaches the fructose part of the sugar onto another sucrose molecule, making a glucose-fructose-fructose chain, and it repeats that process, building up a prebiotic fiber in that process,” explained Sauer.
While the prebiotic properties of FOS are already well established, Zya is undertaking further studies to demonstrate the conversion process and substantiate claims about its ingredient in humans.
The technology is not immediately suitable for all food applications, however. As moisture activates the enzyme, incorporating it directly into products such as yogurt or beverages could trigger conversion before consumption, defeating the purpose of the technology.
Zya is therefore initially focusing on low-moisture applications, with plans to develop formulations that protect the enzyme until it reaches the stomach, potentially opening up a wider selection of categories.
Thermal processing can also pose challenges for enzymes, acknowledged Sauer, who said Zya is working with manufacturers to identify ways of incorporating Convero without compromising its activity.
“There are ways of us getting round certain processing steps that that may inactivate the enzyme,” he said, adding that the goal is “to ensure that we get the enzyme active at the end of the process.”
Validation
To date, Zya has demonstrated Convero’s functionality in in-vitro gut models and preliminary pig studies, with the new funding enabling it to progress to further animal and human studies.
Its commercial feasibility studies involve incorporating Convero into manufacturers’ existing products, assessing sensory characteristics and then testing the finished foods in third-party gastrointestinal models to assess sugar-to-fiber conversion.
Zya has also completed an independent toxicology program, including a 28-day rat feeding study and genotoxicity assessments, with results recently published in Toxicology Reports.
The company is pursuing a self-affirmed Generally Recognized as Safe (GRAS) determination in the US, which it expects to complete by the end of 2026, followed by a formal GRAS submission to the FDA.
Manufacturing and scale up
Convero is manufactured via precision fermentation using an established yeast production platform, with the enzyme recovered from the fermentation process and supplied to food manufacturers as a dry powder.
As there is no trace of the genetically engineered microbe in the extracted enzyme it will not trigger bioengineered labeling in the US, said Sauer.
Zya has demonstrated reproducibility across multiple pilot production runs at a European food-grade manufacturing facility and subsequently scaled production to 10 times the pilot volume.
He did not share numbers but said the cost in use will be commercially viable given the low dosages required.
A labeling challenge: sugar on the shelf, fiber after eating
The unique challenge facing Zya is how to communicate tech that only impacts the nutritional composition of foods post consumption.
A chocolate bar containing Convero, for example, would still contain the same amount of sugar when sold, meaning manufacturers would not be able to lower the declared sugar content on the Nutrition Facts panel. However, text underneath the panel would state something like: “After eating, total sugar = x grams and dietary fiber = x grams.”
On the front of pack, meanwhile, proposed wording might be: “Now with Convero. Converts 30% of sugar into fiber after eating.”
Unlike enzymes used as processing aids, which do not have to be included on ingredients lists, Convero will be declared as a food ingredient, potentially as an “inulosucrase enzyme” followed by something like “sugar to fiber enzyme” in parentheses.
Zya is not planning to make claims about reduced calorie intake or blood glucose response until it has more data, however.
An emerging market for post-consumption sugar reduction
Zya is not alone in exploring approaches that convert sugar into fibers post-ingestion, although its approach differs somewhat, said Sauer.
ZBiotics, for example, has developed a genetically engineered probiotic that produces an enzyme (levansucrase) that converts sucrose into fiber in the digestive tract. BioLumen, in turn, makes microscopic fibrous sponges that expand in the stomach and capture sugars, rendering them unavailable for early absorption in the gut.
Kraft Heinz has also explored post-consumption sugar conversion technology with Wyss Institute researchers, using an enzyme delivery system designed to protect enzymes through the stomach and release them in the small intestine.
Zya’s approach differs in that it supplies the enzyme itself rather than a live microorganism, while its current tech does not require a protective delivery system to remain functional in the stomach, said Sauer.
Unlike ZBiotics, which makes consumer products, Zya also plans to supply Convero directly to large food manufacturers as a branded ingredient.
“The larger companies have demonstrably shown the most interest,” said Sauer, who claimed that several multinationals have completed feasibility projects spanning chocolate, baked goods, bars and confectionery.
“The feedback has been amazing; people have told us this could change the trajectory of the sugar reduction space and see this as a way of making better for you versions of their core, legacy brands without compromising on taste or texture.”
Why investors backed Zya
For investors, said Sauer, the attraction lies in addressing a major nutritional challenge without requiring consumers to change their eating habits or manufacturers to fundamentally rethink their products.
“I think the key thing for our investors was just the uniqueness of what we’re doing,” he said.
The next hurdle will be demonstrating that the conversion observed in laboratory models and preliminary animal studies translates into reproducible results in humans, while establishing a regulatory and claims framework that food manufacturers can confidently adopt.
Further reading:
ZBiotics takes GM probiotics mainstream with 15m+ ‘pre-alcohol’ shots sold
🎥 BioLumen takes novel approach to reducing the glycemic impact of processed foods
BlueTree targets Latam, Southeast Asia, as novel sugar reduction tech gains momentum
Fooditive in advanced talks to commercialize low-cal rare sugar 5-KDF
The post Exclusive: Zya raises $15m Series A to rethink sugar reduction, no reformulation required appeared first on AgFunderNews.